Mozec PEB PTA balloon catheter

Mozec PEB PTA mainMOZECTM PEB is a paclitaxel coated PTA balloon catheter

For treatment of peripheral vessels with an obstructive disease, sub-total or totally occluded vessel. With a drug dose of 3µg/mm², MOZECTM PEB upgrades your efficiency to treat and manage patients with long, diffused disease up to 150mm at one go.

  • Extends your reach of drug treatment - longest length 150mm
  • Securing outcomes with proprietary drug adhesion technology
  • Enhanced navigation with MOZECTM PTA platform 
Supplied By:
Meril

Benefits

  • Longer length balloons (200mm) reduces need for multiple balloons and subsequent exposure time.
  • Proprietary drug adhesion technology ensures minimal drug loss due to physical contact.
  • Improved efficiency - 95% of drug transferred to the vessel wall in the first 30 sec.
  • MOZECTM PTA platform ensures very smooth balloon navigation.
  • Available in both 0.014" and 0.035" and wire compatible.

Product Specifications

PEB PTA 14
PEB PTA 35
Catheter System Over-The-Wire (OTW) Over-The-Wire (OTW)
Balloon Material PEBA PEBA
Drug Type Paclitaxel (Crystalline form) Paclitaxel (Crystalline form)
Drug Dosage 3 µg/mm² 3 µg/mm²
Excipient Poly Ethylene Glycol (PEG-200) + Urea AR grade + Acetone Poly Ethylene Glycol (PEG-200) + Urea AR grade + Acetone
Catheter Usable Length 150 ± 2 cm 135 ± 2 cm
Max Guidewire Compatibility 0.014" 0.035"
Min Sheath Compatibility 4F / 5F (Refer box/IFU for details) 5 - 7F (Refer box/IFU for details)
Distal Purchase 5.0 ± 1 mm 5.0 ± 1 mm
Balloon RO Markers 2 Platinum-Iridium 2 Platinum-Iridium
Nominal Pressure (NP) 6 / 7 atm (Refer compliance chart for details) 6 / 7 atm (Refer compliance chart for details)
Rated Burst Pressure (RBP) 12 - 14 atm (Refer compliance chart for details) 12 - 14 atm (Refer compliance chart for details)

Available Sizes in SA

OTW (0.035" - guidewire compatability)

Diameter: 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 9.00, 10.00mm

Length: 20, 30, 40, 50, 60, 80, 120, 150mm

View brochure

This email address is being protected from spambots. You need JavaScript enabled to view it.